Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease

Borrelli, Francesca; Fasolino, Ines; Romano, Barbara; Capasso, Raffaele; Maiello, Francesco; Coppola, Diana; Orlando, Pierangelo; Battista, Giovanni; Pagano, Ester; Marzo, Vincenzo Di; Izzo, Angelo A.

doi:10.1016/j.bcp.2013.01.017

Cited by 239 publications

(210 citation statements)

References 54 publications

Supporting

Mentioning

201

Contrasting

Unclassified

Order By: Relevance

“…CBG is nonpsychotropic and does not bind or activate CB 1 or CB 2 [17,18]. However, CBG is antioxidant [17,18], as well as anti-inflammatory, as it inhibits lipopolysaccharideinduced (LPS) release of proinflammatory cytokines and prostaglandin E2 in primary microglial cells [19], activates PPARγ [19], and attenuates murine colitis induced by intracolonic administration of dinitrobenzene sulfonic acid [20]. CBG also targets α-2 adrenergic receptors [21], and serves as an antagonist of serotonin 5-hydroxytryptamine 1A receptors (5HT 1A ) [21].…”

Section: Introductionmentioning

confidence: 99%

Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice

Navarrete²,

et al. 2015

View full text Add to dashboard Cite

Different plant-derived and synthetic cannabinoids have shown to be neuroprotective in experimental models of Huntington's disease (HD) through cannabinoid receptordependent and/or independent mechanisms. Herein, we studied the effects of cannabigerol (CBG), a nonpsychotropic phytocannabinoid, in 2 different in vivo models of HD. CBG was extremely active as neuroprotectant in mice intoxicated with 3-nitropropionate (3NP), improving motor deficits and preserving striatal neurons against 3NP toxicity. In addition, CBG attenuated the reactive microgliosis and the upregulation of proinflammatory markers induced by 3NP, and improved the levels of antioxidant defenses that were also significantly reduced by 3NP. We also investigated the neuroprotective properties of CBG in R6/2 mice. Treatment with this phytocannabinoid produced a much lower, but significant, recovery in the deteriorated rotarod performance typical of R6/2 mice. Using HD array analysis, we were able to identify a series of genes linked to this disease (e.g., symplekin, Sin3a, Rcor1, histone deacetylase 2, huntingtin-associated protein 1, δ subunit of the gamma-aminobutyric acid-A receptor (GABA-A), and hippocalcin), whose expression was altered in R6/2 mice but partially normalized by CBG treatment. We also observed a modest improvement in the gene expression for brain-derived neurotrophic factor (BDNF), insulinlike growth factor-1 (IGF-1), and peroxisome proliferatoractivated receptor-γ (PPARγ), which is altered in these mice, as well as a small, but significant, reduction in the aggregation of mutant huntingtin in the striatal parenchyma in CBGtreated animals. In conclusion, our results open new research avenues for the use of CBG, alone or in combination with other phytocannabinoids or therapies, for the treatment of neurodegenerative diseases such as HD.

show abstract

Section: Introductionmentioning

confidence: 99%

Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice

Navarrete²,

et al. 2015

View full text Add to dashboard Cite

show abstract

“…One of the conditions that has increased occurrence in schizophrenic disorder and that raises pain experiences encounters is irritable bowel syndrome [75]. There is evidence that this CBD, extracted from Cannabis sativa plant and also cannabingerol (CBG) extracted from the same plant could be used in the treatment of intestinal inflammation [76,77] and therefore in reducing pain phenomenon caused by this pathology. In addition, our group is also interested in testing pain perception in a rat model of irritable bowel syndrome, and is currently working on a special model of restraint stress-induced intestinal deficits [78] in pain perception and negative symptoms similar to the ones encountered in schizophrenia.…”

Section: Schizophrenia Pain and Plantsmentioning

confidence: 99%

“…Because current results are in need of confirmation we are eager to engage in this controversial research. We present below several plants relevant for pain and/or schizophrenia in the Antihypertensive [51],hypoglycaemic [52], wound healing [53], anti-HIV [54], antidepressant [55], antihelmitic, aphrodisiac [56], treatment of diarrhea, urinary disorders and skin disorders [57] Cannabis sativa (Cannabaceae) cannabidiol (CBD) -neuropathic pain [68,70], inflammatory pain [68], cancer pain [71]; cannabingerol (CBG) -intestinal inflammation pain [76,77]; cannabinoids -cancer pain [71], rheumatoid arthritis pain [72], neuropathic orofacial pain [70]; THC(∆ 9 -tetrahydrocannabidiol) -cancer pain [71] CBDPharmacological profile similar to atypical antipsychotic [69], antipsychotic effect (86) hallucinogen proprieties [67]; ∆ 9 -tetrahydrocannabidiol (THC) -potential schizophrenia outcomes [87]; cannabinoidsimproves spasticity in MS patients [73]; CBDtreatment of intestinal inflammation [76,77] diuretic, anti-emetic, antiepileptic, anti-inflammatory, painkilling and antipyretic properties [97] Corydalis yanhuso (Papaveraceae) Antinociceptive effect in pain animal models, inflammatory pain relief amendment of neuropathic pain [93] anxiolytic properties [98]; primary dysmenorrhea [99]; improve the efficacy of chemotherapy [100]; extract -attenuated cardiac hypertrophy [101]; treatment of various pains [98], insomnia, reducing inflammation and several compounds present antidepressant, antimicrobial and anti-inflammatory activities [95], sedative, and hypnotic properties …”

Section: Schizophrenia Pain and Plantsmentioning

confidence: 99%

Phytotherapeutical implications in pain perception - focusing on schizophrenia

Antioch¹,

Ciobîcă²,

Compaore³

et al. 2017

ijpm

View full text Add to dashboard Cite

A b s t r a c tSc varying from abolition to lack of any kind of changes compared to normal controls and even hypersensitivity. In this way, the hypothesis of amending schizophrenia enhanced the importance of pain medication. But managing pain phenomenon in schizophrenia has large and unknown implications. Nevertheless, pharmacological interactions between the medications for these two entities are unknown and mos side option. ancient knowledge and current scientific pr To our best of knowledge, this is the first time when pain, plants and schizophrenia are discussed together. In this way, it seems that by replacing fully synthesized chemical products, the risk of side have curing effects on the psychotic activities in schizophrenia. Therefore, through this mini ethonopharmacological approaches in pain conditions in the context of schizop highlighted some cases of inappropriate usage of plants in traditional therapy.

show abstract

“…Ikerketa berean, kontrajarria dirudien arren, CBGak PLA 2 entzima aktibatzeko duen gaitasuna ere azaltzen da [22]. Azkenik, CBGak iNOS genearen adierazpena gutxitzen du koloneko zeluletan eta makrofagoetan, berriz, entzima horren produktua den oxido nitrikoaren ekoizpena [33]. Ondorioz, erantzun inmunologikoaren intentsitatea eta horrekin batera hantura ere murrizten ditu.…”

Section: Kannabigerola In Vitro Ereduetan Eta Animalietanunclassified

Kannabinoide berriak: segurtasun eta eraginkortasun terapeutikoaren bila

Aostri

Pineda

Mendiguren

2017

EKAIA

View full text Add to dashboard Cite

Laburpena:Cannabis sativa landarean kannabidiola, kannabigerola edo Δ 9 -tetrahidrokannabibarina bezalako kannabinoide ez-psikoaktiboak aurki daitezke. Oro har, kannabinoide horiek kannabinoideen hartzaileekiko (CB) afinitate txikia dutenez, ez daukate kannabinoide klasikoek (bereziki Δ 9 -THCak) duten aktibitate psikoaktiboa. Gizakietan eta animalietan kannabinoide ez-psikoaktiboekin egindako lehenengo ikerketek horien propietate terapeutikoak frogatu dituzte. Efektu horiek azaltzeko itu eta mekanismo desberdinak proposatu dira, besteak beste, hartzaile serotonergikoen aktibazioa edota entzima desberdinen modulazioa.Hitz gakoak: kannabidiola, kannabigerola, Δ 9 -tetrahidrokannabibarina, kannabinoide, 5-HT 1A hartzailea. Abstract:Cannabis sativa plant contains non-psychoactive phytocannabinoids including cannabidiol, cannabigerol or Δ 9 -tetrahydrocannabivarin. Unlike classical cannabinoids (i.e Δ 9 -THC) most of these compounds bind with low affinity to cannabinoid receptors (CB), which seems to be the reason for their lack of psychoactive effect. Preliminary studies performed in humans and animals demonstrated that these cannabinoids have therapeutic properties. Different targets and mechanisms have been proposed to explain their effects such as activation of serotonergic receptors or modulation of different enzymes.

show abstract

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease

Cited by 239 publications

References 54 publications

Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice

Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice

Phytotherapeutical implications in pain perception - focusing on schizophrenia

Kannabinoide berriak: segurtasun eta eraginkortasun terapeutikoaren bila

Contact Info

Product

Resources

About